Call Options

17 transactions
Quarter Operation Price Per call calls change calls Held SEC Form
Q4 2022

Feb 14, 2023

BUY
$5.77 - $8.49 $224,452 - $330,261
38,900 Added 158.13%
63,500 $31,000
Q3 2022

Nov 14, 2022

BUY
$3.75 - $7.39 $37,125 - $73,161
9,900 Added 67.35%
24,600 $26,000
Q2 2022

Aug 12, 2022

BUY
$2.94 - $5.23 $4,704 - $8,368
1,600 Added 12.21%
14,700 $5,000
Q4 2021

Feb 14, 2022

BUY
$8.96 - $16.31 $9,856 - $17,941
1,100 Added 9.17%
13,100 $12,000
Q3 2021

Nov 10, 2021

SELL
$11.24 - $21.0 $34,844 - $65,100
-3,100 Reduced 20.53%
12,000 $16,000
Q2 2021

Aug 11, 2021

SELL
$18.04 - $22.09 $92,004 - $112,659
-5,100 Reduced 25.25%
15,100 $32,000
Q1 2021

May 14, 2021

BUY
$16.59 - $33.89 $72,996 - $149,116
4,400 Added 27.85%
20,200 $42,000
Q4 2020

Feb 16, 2021

SELL
$27.5 - $37.92 $418,000 - $576,384
-15,200 Reduced 49.03%
15,800 $27,000
Q1 2020

May 08, 2020

BUY
$26.16 - $63.5 $463,032 - $1.12 Million
17,700 Added 133.08%
31,000 $26,000
Q4 2019

Feb 11, 2020

BUY
$46.96 - $61.67 $126,792 - $166,509
2,700 Added 25.47%
13,300 $102,000
Q3 2019

Nov 12, 2019

SELL
$59.47 - $93.1 $41,629 - $65,169
-700 Reduced 6.19%
10,600 $19,000
Q2 2019

Aug 14, 2019

SELL
$75.84 - $105.21 $113,760 - $157,815
-1,500 Reduced 11.72%
11,300 $60,000
Q1 2019

May 10, 2019

BUY
$64.44 - $104.11 $824,832 - $1.33 Million
12,800 New
12,800 $114,000
Q3 2018

Nov 09, 2018

SELL
$88.86 - $117.49 $1.12 Million - $1.48 Million
-12,600 Closed
0 $0
Q2 2018

Aug 13, 2018

SELL
$99.64 - $127.59 $1.1 Million - $1.4 Million
-11,000 Reduced 46.61%
12,600 $11,000
Q4 2017

Feb 09, 2018

BUY
$81.25 - $130.7 $942,500 - $1.52 Million
11,600 Added 96.67%
23,600 $832,000
Q3 2017

Nov 08, 2017

BUY
$57.74 - $91.42 $692,880 - $1.1 Million
12,000
12,000 $315,000

Others Institutions Holding BLUE

About bluebird bio, Inc.


  • Ticker BLUE
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 77,121,800
  • Market Cap $29.3M
  • Description
  • bluebird bio, Inc., a biotechnology company, researches, develops, and commercializes transformative gene therapies for severe genetic diseases. Its product candidates for severe genetic diseases include betibeglogene autotemcel for the treatment of transfusion-dependent ß-thalassemia; lovotibeglogene autotemcel for the treatment of sickle cell ...
More about BLUE
Track This Portfolio

Track Hap Trading, LLC Portfolio

Follow Hap Trading, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Hap Trading, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Hap Trading, LLC with notifications on news.